Diagnostics A Bright Spot In Lackluster US Interventional Cardiology Market
Executive Summary
The US Market for interventional cardiology products, which includes diagnostic and therapeutic products, is anticipated to expand from an estimated $3.3 billion in 2015 to roughly $3.6 billion in total product sales by the year 2020. One bright spot in this otherwise lackluster market is the interventional diagnostic products segment, which is projected to grow at CAGR of 4.7% and reach almost $1 billion by 2020, according to a report by Medtech Insight.
You may also be interested in...
Advisors Provide Lukewarm Endorsement Of St. Jude's PFO Occluder For Stroke
FDA's Circulatory System Devices Panel said that St. Jude's Amplatzer PFO closure device has benefits that outweigh risks to prevent recurrent stroke in a select group of patients on an 11-5 vote, despite having missed its primary endpoint in the pivotal RESPECT trial.
FDA Briefing Docs Appear Positive For Abbott's Absorb, But Adverse Events Highlighted
An FDA panel meets March 15 to discuss Abbott's PMA for the firm's fully absorbable Absorb scaffold. Pre-meeting materials give a generally positive view of the device, but they highlight some elevated adverse-event rates.
INTERVIEW: Bioabsorbable Stents? No, Drug-Filled Stents Is Way Forward, Says Medtronic Cardiac Intervention CMO
The world’s largest medtech pureplay, Medtronic, believes drug-filled stents (DFSs) will be a major advance in coronary stent technology, which is why it is bypassing bioabsorable technologies like Abbott’s Absorb BVS stent and planning its next steps toward bringing DFSs to market.